Faculty Advisor

Adams, David S.

Abstract

Clot dissolvers are enzymes capable of dissolving blood clots that form during heart attacks and strokes. Despite their initial promise as therapeutic agents for these diseases, first generation drugs have shown modest benefits. Our laboratory previously engineered the DNA encoding [of] a second-generation drug comprised of the B-chain of urokinase plasminogen activator (uPA) (a clot dissolver) coupled to factor XI (a targeting component). The purpose of this MQP was to produce this drug in mammalian cells, and to determine if it was active. Using a spectrozyme assay, we show that the catalytic domain of uPA retains activity for its substrate, and is inhibited by known uPA inhibitors.

Publisher

Worcester Polytechnic Institute

Date Accepted

January 1999

Major

Biotechnology

Project Type

Major Qualifying Project

Accessibility

Restricted-WPI community only

Advisor Department

Biology and Biotechnology

Share

COinS